Citadel Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $41.6M | Sell |
519,031
-1,684,896
| -76% | -$139M | 0.01% | 1533 |
|
|
2025
Q4 | $188M | Sell |
2,203,927
-2,030,643
| -48% | -$167M | 0.03% | 510 |
|
|
2025
Q3 | $329M | Sell |
4,234,570
-8,496,721
| -67% | -$664M | 0.05% | 303 |
|
|
2025
Q2 | $996M | Sell |
12,731,291
-650,392
| -5% | -$48.5M | 0.17% | 71 |
|
|
2025
Q1 | $970M | Buy |
13,381,683
+3,963,609
| +42% | +$284M | 0.18% | 58 |
|
|
2024
Q4 | $697M | Buy |
9,418,074
+7,426,571
| +373% | +$520M | 0.12% | 92 |
|
|
2024
Q3 | $131M | Buy |
1,991,503
+1,367,102
| +219% | +$99.3M | 0.03% | 549 |
|
|
2024
Q2 | $57.7M | Sell |
624,401
-2,020,994
| -76% | -$179M | 0.01% | 1047 |
|
|
2024
Q1 | $253M | Buy |
2,645,395
+2,339,486
| +765% | +$197M | 0.05% | 291 |
|
|
2023
Q4 | $23.3M | Sell |
305,909
-284,211
| -48% | -$19.8M | ﹤0.01% | 1861 |
|
|
2023
Q3 | $40.9M | Buy |
590,120
+584,521
| +10,440% | +$47M | 0.01% | 1243 |
|
|
2023
Q2 | $528K | Sell |
5,599
-986,634
| -99% | -$85.8M | ﹤0.01% | 7822 |
|
|
2023
Q1 | $82.1M | Buy |
992,233
+515,843
| +108% | +$40.5M | 0.02% | 729 |
|
|
2022
Q4 | $35.5M | Buy |
476,390
+114,083
| +31% | +$8.79M | 0.01% | 1403 |
|
|
2022
Q3 | $29.9M | Buy |
362,307
+353,476
| +4,003% | +$34M | 0.01% | 1477 |
|
|
2022
Q2 | $840K | Sell |
8,831
-9,460
| -52% | -$979K | ﹤0.01% | 7436 |
|
|
2022
Q1 | $2.15M | Sell |
18,291
-13,713
| -43% | -$1.54M | ﹤0.01% | 5931 |
|
|
2021
Q4 | $4.15M | Sell |
32,004
-147,901
| -82% | -$17.3M | ﹤0.01% | 4670 |
|
|
2021
Q3 | $20.4M | Buy |
179,905
+109,725
| +156% | +$12.5M | ﹤0.01% | 1964 |
|
|
2021
Q2 | $7.27M | Sell |
70,180
-671,205
| -91% | -$63.3M | ﹤0.01% | 3677 |
|
|
2021
Q1 | $62M | Buy |
741,385
+273,466
| +58% | +$23.1M | 0.02% | 871 |
|
|
2020
Q4 | $42.7M | Buy |
467,919
+402,549
| +616% | +$33.4M | 0.01% | 1082 |
|
|
2020
Q3 | $5.22M | Sell |
65,370
-128,859
| -66% | -$10.1M | ﹤0.01% | 3099 |
|
|
2020
Q2 | $13.4M | Sell |
194,229
-1,220,100
| -86% | -$86.7M | ﹤0.01% | 1889 |
|
|
2020
Q1 | $88.9M | Buy |
1,414,329
+1,149,135
| +433% | +$82.9M | 0.04% | 378 |
|
|
2019
Q4 | $20.6M | Sell |
265,194
-2,857,800
| -92% | -$223M | 0.01% | 1445 |
|
|
2019
Q3 | $229M | Buy |
3,122,994
+1,381,560
| +79% | +$97M | 0.11% | 126 |
|
|
2019
Q2 | $107M | Sell |
1,741,434
-708,774
| -29% | -$42.9M | 0.05% | 373 |
|
|
2019
Q1 | $156M | Buy |
2,450,208
+2,445,645
| +53,597% | +$140M | 0.08% | 206 |
|
|
2018
Q4 | $233K | Buy |
+4,563
| New | +$231K | ﹤0.01% | 7644 |
|
|
2018
Q3 | – | Sell |
-216,780
| Closed | -$10.6M | – | 9330 |
|
|
2018
Q2 | $10.5M | Sell |
216,780
-14,046
| -6% | -$656K | 0.01% | 1879 |
|
|
2018
Q1 | $10.7M | Sell |
230,826
-2,996,499
| -93% | -$130M | 0.01% | 1657 |
|
|
2017
Q4 | $121M | Sell |
3,227,325
-787,512
| -20% | -$28.9M | 0.07% | 268 |
|
|
2017
Q3 | $146M | Sell |
4,014,837
-2,178,609
| -35% | -$83.1M | 0.11% | 149 |
|
|
2017
Q2 | $244M | Buy |
6,193,446
+2,626,695
| +74% | +$95.9M | 0.21% | 60 |
|
|
2017
Q1 | $112M | Buy |
3,566,751
+1,011,609
| +40% | +$31.7M | 0.1% | 170 |
|
|
2016
Q4 | $79.8M | Sell |
2,555,142
-2,755,812
| -52% | -$89.3M | 0.08% | 222 |
|
|
2016
Q3 | $213M | Buy |
5,310,954
+4,320,759
| +436% | +$163M | 0.21% | 51 |
|
|
2016
Q2 | $32.9M | Sell |
990,195
-2,827,881
| -74% | -$96.8M | 0.04% | 516 |
|
|
2016
Q1 | $112M | Buy |
3,818,076
+2,479,290
| +185% | +$68.4M | 0.14% | 102 |
|
|
2015
Q4 | $35.2M | Sell |
1,338,786
-11,980,620
| -90% | -$311M | 0.04% | 549 |
|
|
2015
Q3 | $316M | Buy |
13,319,406
+5,826,264
| +78% | +$141M | 0.3% | 37 |
|
|
2015
Q2 | $178M | Buy |
7,493,142
+5,140,596
| +219% | +$116M | 0.15% | 118 |
|
|
2015
Q1 | $55.9M | Buy |
2,352,546
+932,898
| +66% | +$20.9M | 0.05% | 433 |
|
|
2014
Q4 | $30.1M | Sell |
1,419,648
-941,826
| -40% | -$18.9M | 0.03% | 724 |
|
|
2014
Q3 | $40.2M | Buy |
2,361,474
+1,082,874
| +85% | +$17.1M | 0.04% | 521 |
|
|
2014
Q2 | $18.3M | Buy |
1,278,600
+1,170,612
| +1,084% | +$15.9M | 0.02% | 866 |
|
|
2014
Q1 | $1.33M | Sell |
107,988
-20,724
| -16% | -$239K | ﹤0.01% | 3067 |
|
|
2013
Q4 | $1.41M | Sell |
128,712
-689,136
| -84% | -$7.77M | ﹤0.01% | 2872 |
|
|
2013
Q3 | $9.49M | Buy |
817,848
+768,852
| +1,569% | +$8.99M | 0.01% | 1138 |
|
|
2013
Q2 | $549K | Buy |
+48,996
| New | +$580K | ﹤0.01% | 3756 |
|
Other funds holding EW
VCM
VPM
Citadel Advisors's EW Position: Q1 2026 in Review
Citadel Advisors reduced its Edwards Lifesciences (EW) stake by 76% in Q1 2026, selling an estimated $139M and leaving 519,031 shares worth $41.6M. The position accounts for 0.01% of the portfolio, ranked #1533.
Citadel Advisors first reported a position in EW in Q2 2013 and has held it in 51 quarters since. The position peaked at $996M in Q2 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Citadel Advisors held 519,031 shares of Edwards Lifesciences worth $41.6M as of Q1 2026.
- Citadel Advisors sold 1,684,896 Edwards Lifesciences shares in Q1 2026, an estimated $139M.
- Edwards Lifesciences made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1533 holding.
- Citadel Advisors first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 51 quarters since.
- Citadel Advisors's Edwards Lifesciences position peaked at $996M in Q2 2025.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.